Douglas Blayney
Directeur/Membre du Conseil chez ARTELO BIOSCIENCES, INC.
Fortune : 1 118 $ au 30/04/2024
Profil
Douglas W.
Blayney is the founder of Asco Quality Symposium.
He currently holds the position of Independent Director at Artelo Biosciences, Inc. since 2017 and is a Professor at Stanford University since 2010.
Previously, he served as the Medical Director & Professor at the University of Michigan Comprehensive Cancer Center from 1999 to 2003, the Medical Director at Stanford Cancer Institute from 2010 to 2015, and the President of the American Society of Clinical Oncology, Inc. from 2009 to 2010.
He completed his undergraduate education at Stanford University and the University of California.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARTELO BIOSCIENCES INC
0,03% | 22/03/2024 | 834 ( 0,03% ) | 1 118 $ | 30/04/2024 |
Postes actifs de Douglas Blayney
| Sociétés | Poste | Début |
|---|---|---|
| ARTELO BIOSCIENCES, INC. | Directeur/Membre du Conseil | 31/07/2017 |
| Stanford University | Corporate Officer/Principal | 01/07/2010 |
Anciens postes connus de Douglas Blayney
| Sociétés | Poste | Fin |
|---|---|---|
| Stanford Cancer Institute | Corporate Officer/Principal | 01/07/2015 |
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | President | 01/07/2010 |
| University of Michigan Comprehensive Cancer Center | Directeur Technique/Scientifique/R&D | 01/06/2003 |
| Asco Quality Symposium | Fondateur | - |
Formation de Douglas Blayney
| Stanford University | Undergraduate Degree |
| University of California | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ARTELO BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Health Services |
| Stanford Cancer Institute | |
| Asco Quality Symposium |
